Feiba VH Disease Interactions
There is 1 disease interaction with Feiba VH (anti-inhibitor coagulant complex).
Anti- inhibitor coagulation (applies to Feiba VH) thrombo/hemorrhage
Major Potential Hazard, High plausibility. Applicable conditions: History - Thrombotic/Thromboembolic Disorder, Thrombotic/Thromboembolic Disorder, Disseminated Intravascular Coagulation, Myocardial Infarction, Pulmonary Embolism
The use of anti- inhibitor coagulant complex is contraindicated in patients with significant signs of fibrinolysis, disseminated intravascular coagulation (DIC), and acute thrombosis or embolism including myocardial infarction. Anti- inhibitor coagulant complex contains Factor VIII inhibitor bypassing activity and prothrombin complex factors and may cause or exacerbate fibrinolysis or coagulation. If DIC or fibrinolysis occurs during treatment, the infusion should be stopped promptly and appropriate therapeutic measures initiated. Thromboembolic events may also occur during treatment, particularly following the administration of large doses and/or in patients with thrombotic risk factors. Caution is advised when administering anti- inhibitor coagulant complex to patients with an active or past history of thromboembolic disorders.
Switch to professional interaction data
Feiba VH drug interactions
There are 8 drug interactions with Feiba VH (anti-inhibitor coagulant complex).
Report options
More about Feiba VH (anti-inhibitor coagulant complex)
- Feiba VH consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- Drug class: miscellaneous coagulation modifiers
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Lysteda
Lysteda (tranexamic acid) is used to treat heavy menstrual bleeding. Includes Lysteda side effects ...
Hemlibra
Hemlibra is a monoclonal antibody that functions in place of a natural blood-clotting factor that ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
DDAVP
DDAVP is used for diabetes insipidus, hemophilia a, primary nocturnal enuresis, von Willebrand Disease
Altuviiio
Altuviiio is a once-weekly recombinant fact VIII replacement therapy used by hemophilia A patients ...
Qfitlia
Qfitlia is used for hemophilia a, hemophilia a with inhibitors, hemophilia b, hemophilia b with ...
Cyklokapron
Cyklokapron is used for bleeding disorder, factor ix deficiency, hemophilia a
Hympavzi
Hympavzi (marstacimab-hncq) may be used to prevent or reduce the frequency of bleeding episodes ...
Advate
Advate (antihemophilic factor) is used to prevent bleeding episodes in adults and children with ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.